{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:17:12Z","timestamp":1773955032303,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2004,6,9]],"date-time":"2004-06-09T00:00:00Z","timestamp":1086739200000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2004,6]]},"abstract":"<jats:p><jats:bold>Abstract: Background\/Aim: <\/jats:bold> We have previously shown that the histological stage and severity of lymphocytic piecemeal necrosis (LPN) are independent predictive factors of cirrhosis development in ursodeoxycholic acid (UDCA)\u2010treated patients with primary biliary cirrhosis (PBC). Our aim during this study was to determine whether biochemical parameters classically used in PBC management and measured under UDCA could be considered as reliable surrogate markers for these histological prognostic indices in clinical practice.<\/jats:p><jats:p><jats:bold>Method: <\/jats:bold> The study included 153 patients with PBC who had undergone a control liver biopsy after 2 years of UDCA therapy. The relationships between histological and biological features were assessed by variance analysis and logistic regression. The diagnostic value of independent markers was assessed in terms of their sensitivity, specificity, positive predictive value (PPV) and negative value (NPV) and receiver\u2010operating characteristic curves.<\/jats:p><jats:p><jats:bold>Results: <\/jats:bold> Two variables were independently associated with extensive fibrosis (i.e. advanced histological stages): serum levels of bilirubin and hyaluronic acid (HA). A fibrosis index ([bilirubin (\u03bcmol\/l)\/14]+[HA (\u03bcg\/l)\/143]) higher than 1.5 exhibited good PPV and specificity (&gt;74%) but rather poor NPV and sensitivity (&lt;64%) regarding a diagnosis of extensive fibrosis. The only independent marker of LPN was aspartate aminotransferase (AST) activity. AST activity of more than twice the upper limit of normal showed acceptable PPV (&gt;70%) but very low sensitivity (&lt;25%) for a diagnosis of LPN.<\/jats:p><jats:p><jats:bold>Conclusions: <\/jats:bold> Serum bilirubin and HA levels measured under UDCA therapy are of acceptable diagnostic value for extensive fibrosis, but none of the biochemical tests commonly employed in the management of PBC can be considered as surrogate markers of LPN. Taken together with our previous results, these findings suggest that liver biopsy may be necessary to screen UDCA\u2010treated patients who might require additional therapies.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2004.0918.x","type":"journal-article","created":{"date-parts":[[2004,6,9]],"date-time":"2004-06-09T12:38:03Z","timestamp":1086784683000},"page":"187-193","source":"Crossref","is-referenced-by-count":39,"title":["Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA\u2010treated patients with primary biliary cirrhosis"],"prefix":"10.1111","volume":"24","author":[{"given":"Christophe","family":"Corpechot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armelle","family":"Poujol\u2010Robert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Wendum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Galotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Chr\u00e9tien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9e Eug\u00e9nie","family":"Poupon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raoul","family":"Poupon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,6,9]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/he.2000.5984"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105303242204"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90021-3"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840190512"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840220311"},{"key":"e_1_2_6_7_2","first-page":"561","article-title":"Long\u2010term effects of ursodeoxycholic acid in primary biliary cirrhosis","volume":"32","author":"Pares A","year":"2000","journal-title":"results of a double-blind controlled multicentric trial"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.20240"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)70183-5"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)72401-6"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290140"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510230532"},{"key":"e_1_2_6_13_2","first-page":"652","article-title":"Primary biliary cirrhosis","volume":"122","author":"Corpechot C","year":"2002","journal-title":"incidence and predictive factors of cirrhosis development in ursodiol-treated patients"},{"key":"e_1_2_6_14_2","first-page":"296","article-title":"Primary biliary cirrhosis\u2010autoimmune hepatitis overlap syndrome","volume":"28","author":"Chazouilleres O","year":"1998","journal-title":"clinical features and response to therapy"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290444"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80098-1"},{"key":"e_1_2_6_17_2","first-page":"409","article-title":"Primary biliary cirrhosis with additional features of autoimmune hepatitis","volume":"35","author":"Joshi S","year":"2002","journal-title":"response to therapy with ursodeoxycholic acid"},{"key":"e_1_2_6_18_2","first-page":"1069","article-title":"Biochemical markers of liver fibrosis in patients with hepatitis C virus infection","volume":"357","author":"Imbert\u2010Bismut F","year":"2001","journal-title":"a prospective study"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(94)80013-8"},{"key":"e_1_2_6_20_2","first-page":"635","article-title":"Predictive factors in ursodeoxycholic acid\u2010treated patients with primary biliary cirrhosis","volume":"19","author":"Poupon R E","year":"1994","journal-title":"role of serum markers of connective tissue"},{"key":"e_1_2_6_21_2","first-page":"343","volume-title":"Autoimmune Liver diseases","author":"Gordon S C.","year":"1998"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00006-0"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.46.1.121"},{"key":"e_1_2_6_24_2","first-page":"1044","article-title":"Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis","volume":"123","author":"Prince M I","year":"2002","journal-title":"follow-up for up to 28 years"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2004.0918.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2004.0918.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/j.1478-3231.2004.0918.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2004.0918.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T15:34:28Z","timestamp":1692718468000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2004.0918.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["10.1111\/j.1478-3231.2004.0918.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2004.0918.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}